High Intensity Focused Ultrasound


High Intensity Focused Ultrasound is a non-invasive acoustic ablation technique that uses high frequency ultrasound waves to heat and destroy cancer cells in the prostate.

HIFU is one of the treatments for prostate cancer that is completely localised within the prostate and has not spread to other areas of the body.


Acoustic ablation uses intersecting, tightly focused ultrasound waves to raise the temperature of the target tissue to more than 80-90 degrees Celsius in two to three seconds, effectively destroying the tissue.

  • Significantly less pain
  • Less blood loss
  • Fewer complications
  • Less scarring
  • A shorter hospital stay and quicker return to normal daily activities

Ultrasound energy is non-ionizing “clean energy” that does not affect tissue surrounding the target zone, as opposed to radiation therapies.

HIFU treatment in approved countries can be given in one to four hours on an outpatient basis with epidural anaesthesia.

HIFU is being studied around the world to treat all types of cancer and soft tissue diseases.

Researchers in UCH, London have presented a research study to fellow surgeons and oncologists at the British Prostate Group, with 83% of men treated to a PSA nadir of 0.2ng/ml or less. This very low level of PSA is used as a marker by more established techniques such as radiotherapy to predict cancer cure rates at 10 years. The PSA level can be reached after just 3 months with HIFU treatment, giving men early peace of mind that they have been successfully treated.

Mr Chris Ogden

Mr Christopher Ogden was one of the first urologists to use HIFU treatment which began at the same time as his pioneering work in robotic surgery.

He is one of the few surgeons in the world who has assessed the comparisons between whole gland HIFU and robotic surgery. He has co-authored a paper on the outcomes of whole gland HIFU which was accepted for publication in the Journal of Urology.

He is also one of the leading Consultants in the multicentre index trial. The index trial focuses on the clinical effectiveness of focal HIFU and promises to offer certain men better functional outcomes with regards to treatment for prostate cancer. It carefully assesses the early oncological outcomes which have been encouraging in small groups of patients with early follow up.

Mr Christopher Ogden Mr Christopher Ogden

Contact us

Please get in touch for further information.

Tel: 020 7603 6067
back to top